Skip to Content

AdreView Approval History

  • FDA approved: Yes (First approved September 19th, 2008)
  • Brand name: AdreView
  • Generic name: iobenguane I 123
  • Dosage form: Injection
  • Company: GE Healthcare
  • Treatment for: Diagnosis and Investigation

AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Development History and FDA Approval Process for AdreView

Sep 19, 2008Approval FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.